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Abstract 23 
 24 
Glucocorticoids are steroid hormones that are secreted upon stress. Their effects are mediated by 25 
the glucocorticoid receptor (GR) which acts as a transcription factor. Since the anti-inflammatory 26 
activity of glucocorticoids has been well established, they are widely used clinically to treat 27 
many inflammatory and immune-related diseases. However, the exact specificity, mechanisms 28 
and level of regulation of different inflammatory pathways have not been fully elucidated. In the 29 
present study, a tail fin amputation assay was employed in 3-day-old zebrafish larvae to study the 30 
immunomodulatory effects of the synthetic glucocorticoid beclomethasone. First, a 31 
transcriptome analysis was performed, which showed that upon amputation mainly immune-32 
related genes are regulated. This regulation was inhibited by beclomethasone for 86% of 33 
regulated genes. For two immune-related genes, tlr4bb and alox5ap, the amputation-induced 34 
increase was not attenuated by beclomethasone. Alox5ap is involved in eicosanoid biosynthesis, 35 
but the increase in LTB4 concentration upon amputation was abolished, and LXA4 levels were 36 
unaffected by beclomethasone. Furthermore, we studied the migration of neutrophils and 37 
macrophages towards the wound site. Our results show that amputation induced migration of 38 
both types of leukocytes, and that this migration was dependent on de novo protein synthesis. 39 
Beclomethasone treatment attenuated the migratory behavior of neutrophils in a GR-dependent 40 
manner, but left the migration of macrophages unaffected. In conclusion, beclomethasone has a 41 
dramatic inhibitory effect on the amputation-induced pro-inflammatory gene regulation, and this 42 
is reflected in an inhibition of the neutrophil migration, but not the migration of macrophages, 43 
which are likely to be involved in inflammation resolution.  44 
Introduction 45 
 46 
Glucocorticoids (GCs) regulate a wide range of biological processes, such as our immune 47 
response, metabolism, growth, reproduction, vascular tone, bone formation, and brain function 48 
(1-6). Because of their anti-inflammatory effects, they are widely used clinically for the 49 
treatment of many immune-related diseases, like asthma, rheumatoid arthritis and leukemia (7,8). 50 
These effects are mediated by the glucocorticoid receptor (GR), which acts as a ligand-activated 51 
transcription factor. In its inactive state, the GR resides within the cytoplasm, and upon GC 52 
binding it translocates to the nucleus, where it acts as a transcription factor and orchestrates gene 53 
expression (9). GRs may occupy glucocorticoid response elements (GREs) and recruit 54 
transcriptional coregulators, which results in a positive or negative regulation of the transcription 55 
rate of nearby target genes. GRs may also interact with other transcription factors, e.g. NF-κB or 56 
AP-1, and repress their activity (1,2,4,10-12). This mode of action has long been considered the 57 
main mechanism by which GCs exert their anti-inflammatory effects, since it results in a 58 
downregulation of the expression of a large number of inflammatory mediators (1,2,9-13). 59 
However, recent evidence shows that the picture appears to be more complex (14,15). For 60 
example, repression of genes is commonly a result of GRE occupancy as well, and GR 61 
interaction with transcription factors like NF-κB or AP-1 appears to enhance gene transcription 62 
in about half of all cases where this interaction was observed (14). 63 
Many in vitro and in vivo studies have been performed to elucidate the cellular and 64 
molecular pathways within the immune system that are affected by GR signaling (16,17). From 65 
these studies it appeared that GCs suppress inflammation by downregulating the expression of a 66 
wide variety of genes for pro-inflammatory cytokines (e.g. IL1β, IL6, TNFα), chemokines (e.g. 67 
CCL1, CXCL8), enzymes (e.g. iNOS, COX-2) and adhesion molecules (e.g. ICAM-1), while the 68 
gene expression of several anti-inflammatory mediators is upregulated (e.g. DUSP1, IκB, IL10, 69 
TGFβ, ANXA1, GILZ) (8,18-20). Furthermore, the synthesis of pro-inflammatory agents like 70 
prostaglandins, proteolytic enzymes, free oxygen radicals, and nitric oxide is also inhibited by 71 
GCs (18). However, several studies have revealed immunoenhancing effects of GCs, like the 72 
induction of Toll-like Receptor (TLR)2 and TLR4, the secretion of MIF (Macrophage Inhibitory 73 
Factor) and the upregulation of IL7Ra and serpinA3 (18,21,22).  74 
The aim of the present study is to establish and exploit a robust in vivo model to 75 
investigate in detail the molecular mechanism of the anti-inflammatory action of GCs. A better 76 
understanding of the complex interplay of GR with the different components of the immune 77 
response would be of great importance to improve GC therapies, since the clinical use of GCs is 78 
currently limited by the deleterious side effects and the occurrence of resistance to GC treatment 79 
(23,24). 80 
Over the last decade, the zebrafish has emerged in biomedical research as an important 81 
model system for a variety of human diseases (25-27). The zebrafish immune system remarkably 82 
resembles that of mammals (28), thus providing an excellent system for modeling various 83 
molecular and cellular elements of inflammation such as host-pathogen interactions during 84 
infectious diseases and immune cell migration to wound sites (29,30). In the present study, 85 
zebrafish larvae are used at three days post fertilization (dpf). At this stage, two types of 86 
leukocytes are present which constitute the innate immune system, macrophages and neutrophils 87 
(31-35). Cells representing the adaptive immune system, like lymphocytes, do not mature before 88 
the second week of zebrafish development (36-38). Furthermore, the zebrafish is used as a model 89 
organism for GC research (39-44). Zebrafish have a single GR gene which encodes a GR protein 90 
that upon activation mediates gene transcription in a similar way as its human equivalent 91 
(39,42,45-48). Local inflammation can be modeled in zebrafish by amputation of the tail fin of 92 
zebrafish larvae (49). Amputation induces the expression of many pro-inflammatory mediators at 93 
the wound site and migration of neutrophils and macrophages, towards the site of amputation 94 
(46,49-53). Interestingly, it has been demonstrated that this migration is inhibited by 95 
glucocorticoid treatment and therefore this model system enables studying of the anti-96 
inflammatory action of glucocorticoids in an in vivo situation (46,51). 97 
In the present study we have used the zebrafish tail fin amputation model to study 98 
glucocorticoid effects on changes in gene expression at the whole transcriptome level and 99 
associated leukocyte migration. Our results demonstrate that tail fin amputation affects the 100 
expression of a wide variety of genes, among which many inflammation-related ones, and that 101 
glucocorticoid treatment attenuates the vast majority of these changes. In contrast, glucocorticoid 102 
treatment specifically inhibits the migration of neutrophils towards the wounded area, but leaves 103 
macrophage migration unaffected.  104 
Materials & Methods 105 
 106 
Zebrafish, husbandry & egg collection 107 
Zebrafish were maintained and handled according to the guidelines from the Zebrafish Model 108 
Organism Database (ZFIN, http://zfin.org) and in compliance with the directives of the local 109 
animal welfare committee of Leiden University. Fertilization was performed by natural spawning 110 
at the beginning of the light period and eggs were raised at 28.5°C in egg water (60μg/ml Instant 111 
Ocean sea salts supplemented with 0.0025% methylene blue (GUUR)). The grs357 mutant line 112 
(previously described by Ziv et al. (54) was provided by Dr. H. Baier (Max Planck Institute of 113 
Neurobiology, Martinsried, Germany). 114 
 115 
Tail amputation &chemical treatments 116 
Three-day-old embryos were anesthetized in egg water containing 0.02% buffered aminobenzoic 117 
acid ethyl ester (tricaine, Sigma) and aligned in Petri dishes coated with 2% agarose for 118 
subsequent partial amputation of the tail fin as shown in Fig.1A. Amputation was performed 119 
using a 1mm sapphire blade (World Precision Instruments) using a Leica M165C stereo-120 
microscope and a micromanipulator. Amputated and non-amputated embryos were pretreated for 121 
2h with either 25μM beclomethasone (Sigma) or vehicle (0.05% DMSO) prior to amputation and 122 
again for a specified period of time after amputation. The relatively high dose of beclomethasone 123 
was chosen based on studies by Mathew et al. (51), who showed this dose to be maximally 124 
effective in zebrafish. Cycloheximide treatment (50 µg/ml, Sigma) was performed similarly. For 125 
gene expression analysis samples were collected in TRIzol® reagent (Invitrogen), for ELISA 126 
samples were snap frozen in liquid nitrogen, and for migration studies samples were fixed in 4% 127 
paraformaldehyde (PFA) in phosphate-buffered saline (PBS) and stored at 4°C.  128 
 129 
RNA isolation & cDNA synthesis 130 
Total RNA was extracted using TRIzol® reagent (Invitrogen) according to the manufacturer’s 131 
instructions (Invitrogen). RNA was dissolved in water and denatured for 5min at 60°C. Samples 132 
were treated with DNAse using the DNA-free™ kit (Ambion). For microarray analysis, RNA 133 
was further purified using the RNeasy MinEluteTM Cleanup kit from Qiagen and its integrity was 134 
checked with a lab-on-chip analysis using the 2100 Bioanalyzer (Agilent Technologies). For 135 
subsequent cDNA synthesis, 1μg of total RNA was added as a template for reverse transcription 136 
using the iSCRIPTTM cDNA Synthesis Kit (Biorad). 137 
 138 
Microarray design 139 
A 4x180k microarray chip platform (customized by Agilent Technologies, (Design ID:028233)) 140 
was used in this study. This array consists of all probes already present in an earlier 45.219 141 
custom-made array (55), and another 126.632 newly designed zebrafish probes had been added 142 
as described in (56). A total of 16 samples (4 experimental groups from 4 replicate experiments) 143 
were processed for transcriptome analysis and were hybridized against a common reference 144 
sample, consisting of a mixture of all samples used in this study.  145 
 146 
Microarray amplification & labeling 147 
Amplification and labeling of RNA was performed at the MicroArray Department (MAD) of the 148 
University of Amsterdam (Amsterdam, The Netherlands). Per sample, 0.5μg total RNA was 149 
amplified and combined with Spike A according to the Agilent Two-Color Microarray-Based 150 
Gene Expression Analysis kit (Agilent technologies). As a common reference sample an 151 
equimolar pool of all test samples was made and 0.5μg samples were amplified similarly as the 152 
test samples with the exception that Spike B was used. Amino-allyl modified nucleotides were 153 
incorporated during the aRNA synthesis (2.5mM of each GTP, ATP, UTP (GE Healthcare), 154 
0.75mM CTP (GE Healthcare), 0.3mM AA-CTP (TriLink Biotechnologies)). Synthesized aRNA 155 
was purified with the E.Z.N.A. MicroElute RNA Clean Up Kit (Omega Bio-Tek). The quality 156 
was inspected on the BioAnalyzer (Agilent Technologies) with the Agilent RNA 6000 kit 157 
(Agilent Technologies). Test samples were labeled with Cy3 and the reference sample was 158 
labeled with Cy5. Five μg of aRNA was dried out and dissolved in 50mM carbonate buffer pH 159 
8.5. Individual vials of Cy3/Cy5 from the mono-reactive dye packs (GE Healthcare) were 160 
dissolved in 200μl DMSO. To each sample, 10μl of the appropriate CyDye dissolved in DMSO 161 
was added and the mixture was incubated for 1h. Reactions were quenched with the addition of 162 
5μl 4M hydroxylamine (Sigma-Aldrich). The labeled aRNA was purified with the E.Z.N.A. 163 
MicroElute RNA Clean Up Kit. Yields of aRNA and CyDye incorporation were measured on the 164 
NanoDrop ND-1000. 165 
 166 
Microarray hybridization, scanning & data processing 167 
Each hybridization mixture was made up from 825ng Test (Cy3-labeled) and 825ng Reference 168 
(Cy5-labeled) material. Hybridization mixtures were using the Agilent Two-Color Microarray-169 
Based Gene Expression Analysis kit according to the manufacturer’s instructions (Agilent 170 
technologies). The samples were loaded onto the microarray chips and hybridized for 17h at 171 
65°C. Afterwards the slides were washed and scanned (20 bit, 3µm resolution) in an ozone-free 172 
room with the Agilent G2505C scanner. Data was extracted with Feature Extraction (v10.7.3.1, 173 
Agilent Technologies) with the GE2_107_Sep09 protocol for two-color Agilent microarrays. 174 
The Agilent output from the 16 hybridizations was then imported into the Rosetta Resolver 7.2 175 
software (Rosetta Biosoftware, Seattle, Washington) and subjected to a factorial design with a 176 
re-ratio with common reference application. Data analysis was performed setting cutoff for the p-177 
value of <10-10 and for fold change of either >2 or <-2. The raw data were submitted to the Gene 178 
Expression Omnibus (GEO) database under accession number GSE69444. 179 
 180 
Gene Ontology analysis 181 
Gene ontology analysis of the microarray results was performed as described previously (44). As 182 
a starting point, clusters of genes were analyzed using the online functional classification tool 183 
DAVID (http://david.abcc.ncifcrf.gov/summary.jsp). In addition, for genes not classified by 184 
DAVID, information was gathered on their function (using the websites GeneCards 185 
(http://www.genecards.org/), NCBI (http://www.ncbi.nlm.nih.gov/gene), Genetics Home 186 
Reference (http://www.ncbi.nlm.nih.gov/gene) and Wikipedia (http://en.wikipedia.org/wiki/). 187 
Using this information, all genes were classified in one of the categories assigned by DAVID, or 188 
in a new category. 189 
 190 
Quantitative Polymerase Chain Reaction (qPCR)  191 
QPCR analysis was performed using the MyiQ Single-Color Real-Time PCR Detection System 192 
(Biorad). PCR reactions were performed in a total volume of 25μl containing 6.5μl diluted 193 
cDNA, 1μl forward and reverse primer (10μM) and 12.5μl of 2x iQ™ SYBR® Green Supermix 194 
(Biorad). Cycling conditions were 95°C for 3min, followed by 40 cycles of 15sec at 95°C, 30sec 195 
at 60°C and 30sec at 72°C. Ct values (cycle number at which a threshold value of the 196 
fluorescence intensity was reached) were determined for each sample. A dissociation protocol 197 
was added, determining dissociation of the PCR products from 65°C to 95°C, allowing 198 
discrimination of specific products. In all qPCR experiments, a water-control was included. Data 199 
shown are means (± s.e.m.) of four individual experiments. In each experiment, cDNA samples 200 
were assayed in duplicate. Sequences of all primers used for qPCR analysis are presented in 201 
Suppl. Table 1, and a phylogenetic tree showing all zebrafish arachidonate lipoxygenase (alox) 202 
genes is shown in Suppl.Fig.1. 203 
 204 
LTB4 and LXA4 ELISA 205 
For each data point, six samples (20 larvae each) were collected. All liquid was removed and 206 
samples were snap frozen in liquid nitrogen. For ELISA, 250µl 1x PBS and 0.2 SSB02 stainless 207 
steel beads (Next advance) were added to each sample. Larvae were homogenized using the 208 
Bullet blender® (Next advance) for 3min on speed 8. The samples were then centrifuged at 3500 209 
rpm for 5min. The supernatant was collected and centrifuged again at 5000 rpm for 5 min after 210 
which the supernatant was collected again. An LTB4 ELISA kit (Enzo Life Sciences), and LXA4 211 
ELISA kit (Cloud-Clone) were used according to the manufacturer’s instructions. All samples 212 
were measured in duplicate (100 µl used per measurement), and the data from the duplicates was 213 
averaged. Data shown are the averages (± s.e.m.) from six replicates. 214 
 215 
 216 
 217 
Myeloperoxidase staining and whole mount immunohistochemistry for visualization of 218 
macrophages and neutrophils 219 
Embryos were fixed in 4% PFA overnight at 4°C and following washes with PBS containing 220 
0.1% Tween 20 (PBST), the Myeloperoxidase (mpx) activity was detected using the Leukocyte 221 
Peroxidase kit (Sigma) according to the manufacturer’s instructions. Mpx staining was always 222 
performed prior to L-plastin immunohistochemistry. For this purpose, embryos were washed in 223 
PBST, gradually dehydrated with methanol in PBS and stored in 100% methanol overnight at 224 
4°C. The next day embryos were rehydrated with graded series of methanol in PBS containing 225 
0.8% Triton X-100 (PBS-TX) and incubated with 10μg/ml Proteinase K (Roche) for 10min at 226 
37°C. Embryos were then incubated in PBS-TX blocking buffer (containing 1% BSA) for 2h at 227 
RT and subsequently in blocking buffer containing a rabbit anti-L-plastin polyclonal antibody 228 
(provided by Dr. A. Huttenlocher (57), 1:500 dilution) overnight at 4°C. Following washes with 229 
PBS-TX, embryos were incubated again in blocking buffer for 1h at RT prior to incubation with 230 
goat anti-rabbit Alexa Fluor® 568 dye–labeled secondary antibody (Invitrogen) for 2h at RT 231 
(1:200 dilution in blocking buffer).  232 
Imaging of the embryos was performed using a Leica MZ16FA fluorescence stereo-233 
microscope supported by the LAS version 3.7 software. Macrophages were detected based on the 234 
red fluorescent labeling by the immunohistochemistry and neutrophils were detected based on 235 
their dark brown appearance as a result of the Mpx assay (although they are stained by both 236 
methods, the L-plastin immunolabeling is hard to detect in these cells due to the dark staining of 237 
the Mpx assay). To determine the number of cells that had migrated to the wounded area, the 238 
cells posterior to the caudal vein were counted (see also Suppl.Fig.6). Data shown are means (± 239 
s.e.m.) of three individual experiments. In each experiment, treatment groups consisted of at least 240 
20 larvae. 241 
 242 
Statistical analysis 243 
Statistical analyses (one- or two-way ANOVAs with Bonferroni post-hoc tests) were performed 244 
using the GraphPad Prism version 4.00 (GraphPad Software, La Jolla, USA).  245 
Results 246 
Analysis of GC effects on the transcriptional response to wounding using the zebrafish tail 247 
fin amputation assay 248 
In order to study the anti-inflammatory action of GCs in zebrafish, we set up a tail fin amputation 249 
assay using 3 day post fertilization (dpf) larvae that were exposed to either vehicle or the 250 
synthetic GC beclomethasone (25μM) for 2h. Tail fins were amputated and vehicle or 251 
beclomethasone treatment was continued. Total RNA samples were collected at 4 h post 252 
amputation (hpa). This way, four experimental groups were generated: control  treated with 253 
vehicle (con/vehicle), amputated treated with vehicle (4hpa/vehicle), control treated with 254 
beclomethasone (con/beclo), and amputated treated with beclomethasone (4hpa/beclo). The 255 
samples were used in a microarray experiment to analyze the transcriptional response to 256 
wounding as well as how this response was affected by beclomethasone treatment. 257 
 258 
The effects of amputation on gene transcription  259 
First, we identified 380 probes to be significantly regulated due to amputation (comparison 260 
con/vehicle vs. 4hpa/vehicle). Gene annotation demonstrated that these probes corresponded to 261 
279 genes, of which 201 were upregulated and 78 downregulated due to amputation. Gene 262 
ontology analysis revealed that 31 genes in this cluster were involved in the immune system. Of 263 
these 31 genes, 3 encoded anti-inflammatory proteins, 9 were involved in chemokine or cytokine 264 
signaling, and 4 were involved in prostaglandin or leukotriene signaling. Furthermore, 29 genes 265 
encoding transcription factors (or other proteins involved in transcriptional regulation) were 266 
present in this amputation-regulated cluster. The two most strongly upregulated transcription 267 
factor genes (fos and atf3) are both members of the AP-1 transcription factor family, and another 268 
member of this family (mafk) was upregulated as well. Several other genes encoding 269 
transcription factors known to activate immune-related genes, like irf9 and stat3 were also 270 
upregulated. Genes involved in metabolic processes also formed a large gene ontology group 271 
within this cluster, and were represented by 25 genes. Of these genes, 8 were involved in 272 
carbohydrate metabolism, 14 in protein metabolism and 2 in lipid metabolism. An overview of 273 
the gene ontology analysis is presented in Fig.1B, and detailed information is presented in 274 
Suppl.Table2.  275 
 276 
The effects of beclomethasone on gene transcription  277 
Subsequently, we investigated which genes responded to beclomethasone treatment in non-278 
amputated larvae. A cluster of 927 probes was identified to be significantly regulated due to 279 
beclomethasone treatment (comparison con/vehicle vs. con/beclo). Gene annotation 280 
demonstrated that these probes corresponded to 506 genes (Fig.1B), of which 420 were 281 
upregulated and 86 downregulated due to beclomethasone. Gene ontology analysis showed that 282 
90 genes in this cluster were involved in metabolic processes, of which 19 in the metabolism of 283 
carbohydrates, 28 in protein metabolism, and 13 in lipid metabolism. Other gene ontology 284 
groups overrepresented in this cluster were those containing genes involved in membrane 285 
transport (37 genes), cell cycle and apoptosis (30), and genes encoding transcription factors (30). 286 
An overview of the gene ontology analysis of this cluster is presented in Suppl.Fig.2A and B, 287 
and detailed information is presented in Suppl.Table3. A number of 32 genes were present in 288 
both the amputation- and the beclomethasone-regulated cluster of genes (Fig.1C and 289 
Suppl.Table3). This cluster may represent the genes that are regulated upon amputation due to 290 
increased cortisol levels. 291 
 292 
The effects of amputation and beclomethasone on gene transcription  293 
Next, we were interested in genes that were significantly changed due to the combination of 294 
amputation and beclomethasone treatment (comparison con/vehicle vs. 4hpa/beclo). We 295 
identified 1075 probes to be significantly regulated and gene annotation revealed that these 296 
probes corresponded to 594 genes, of which 459 were upregulated and 135 were downregulated. 297 
Gene ontology analysis demonstrated that this cluster very much resembles the beclomethasone-298 
regulated gene cluster. For example, the largest gene ontology group were the genes involved in 299 
metabolism (Suppl.Fig.2A and B and Suppl.Table4), and 315 genes from the cluster of 506 300 
beclomethasone-regulated genes were present in this cluster as well (Fig.1C). In contrast, only 61 301 
genes from the cluster of 279 amputation-regulated genes were present in this cluster (Fig.1C). 302 
Apparently, gene regulation by amputation is attenuated by beclomethasone treatment.  303 
To study how beclomethasone changes the amputation-induced changes in gene 304 
expression, we plotted the level of regulation by amputation and beclomethasone (comparison 305 
con/veh vs. amp/beclo) against the regulation by amputation (comparison con/veh vs. amp/veh) 306 
for all probes significantly regulated upon amputation (Fig.2). The resulting scatter plot shows 307 
that of all probes regulated by amputation, 86% shows an attenuation of this regulation upon 308 
amputation in the presence of beclomethasone. This indicates that beclomethasone has a 309 
dramatic inhibitory effect on the amputation-induced changes in gene expression, affecting 310 
almost the entire transcriptional response to amputation. For comparison, a similar plot was 311 
made in which the level of regulation by amputation and beclomethasone (comparison con/veh 312 
vs. amp/beclo) was plotted against the regulation by beclomethasone (comparison con/veh vs. 313 
con/beclo). This plot (Suppl.Fig.3) shows that the regulation by beclomethasone was attenuated 314 
upon amputation and beclomethasone treatment in only 62% of probes. Thus, the effect of 315 
beclomethasone on amputation-induced changes is much stronger than the effect of amputation 316 
on the total group of beclomethasone-regulated genes. 317 
 The regulation of immune system-related genes by amputation and beclomethasone was 318 
subsequently studied in more detail. Of the 31 immune-related genes that were regulated by 319 
amputation, we plotted the regulation by amputation (con/veh vs. amp/veh), beclomethasone 320 
(con/veh vs. con/beclo), and the combination of amputation and beclomethasone (con/veh vs. 321 
amp/beclo). As expected, the results show that most amputation-induced changes in immune 322 
gene expression are attenuated upon amputation in the presence of beclomethasone (Fig.3). By 323 
means of qPCR, the regulation of 4 immune-related genes was verified (Suppl.Fig.4). 324 
Additionally, we plotted the regulation of the 29 transcription factor genes that were observed to 325 
be induced by amputation (Suppl.Fig.5). The induction of only 6 transcription factor genes was 326 
resistant to beclomethasone treatment. Of the 23 other transcription factor genes (among which 327 
many known to have pro-inflammatory action) the induction was attenuated by beclomethasone. 328 
For 4 immune-related genes the induction upon amputation was not attenuated by 329 
beclomethasone treatment. Of these 4 genes, 2 encoded anti-inflammatory proteins (cd22 and 330 
anxa1a), and 2 encoded pro-inflammatory proteins (alox5ap and tlr4bb). 331 
 332 
The effects of amputation and beclomethasone on leukotriene biosynthesis 333 
The observed regulation of the alox5ap (arachidonate 5-lipoxygenase-activating protein) gene is 334 
particularly interesting since Alox5ap activates the Alox5 protein. Alox5 is  known to be 335 
involved (together with Leukotriene A4 hydrolase (Lta4h)) in the biosynthesis of Leukotriene B4 336 
(LTB4), which plays an important role as a chemoattractant for leukocyte migration 337 
(biosynthesis pathway shown in Fig.4A). Therefore, it was studied whether the observed alox5ap 338 
gene regulation was translated into altered LTB4 levels. An LTB4 ELISA was performed on 339 
homogenates taken from control and amputated larvae in the absence and presence of 340 
beclomethasone at 4hpa. The results show an almost three-fold increase in LTB4 concentration 341 
upon amputation, and interestingly this increase is abolished in the presence of beclomethasone 342 
(Fig.4B).  343 
Subsequently, we studied whether transcriptional regulation of the expression of enzymes 344 
involved in the LTB4 biosynthesis pathway could explain the alterations in LTB4 levels. For this 345 
purpose, we determined mRNA levels for alox5ap, alox5a, and lta4h using qPCR (alox5b.1-3 346 
mRNA levels were too low to be detected by qPCR). The regulation of the alox5ap gene as 347 
observed in the microarray was verified (Fig.4C). Furthermore, alox5a and lta4h mRNA levels 348 
were decreased by amputation, and beclomethasone increased the expression of lta4h (Fig.4D 349 
and E). Thus, although the amputation-induced increase in alox5ap mRNA expression (observed 350 
in the microarray and confirmed by qPCR) was not inhibited by beclomethasone, the increase in 351 
LTB4 levels upon amputation was blocked by beclomethasone treatment. This discrepancy could 352 
not be explained by the regulation of other genes involved in the LTB4 biosynthesis. 353 
Alternatively, beclomethasone may regulate eicosanoid biosynthesis downstream of 354 
LTA4 as well, and could for example stimulate conversion of LTA4 to lipoxinA4 (LXA4) 355 
(pathway shown in Fig.5A). An LXA4 ELISA was performed to test this hypothesis. The results 356 
showed that amputation decreased the LXA4 concentrations and that beclomethasone did not 357 
affect this decrease (Fig.5B), thereby falsifying the hypothesis. Expression of three genes 358 
involved in this pathway, alox12, alox12b and alox15b, determined by qPCR could explain the 359 
LXA4 data (Figs.5C-D). The qPCR results showed that amputation decreases the expression of 360 
these genes and this decrease is only affected by beclomethasone for alox12.  361 
 362 
The tail fin amputation assay to study GC effects on leukocyte migration  363 
Previous studies in zebrafish larvae have shown that leukocytes migrate to wound sites, 364 
representing an inflammatory response, and that this response is impaired upon treatment with 365 
GCs (46,51). In order to study this in more detail, tail fins were amputated upon vehicle or 366 
beclomethasone treatment as described above. Larvae were fixated at 0, 2, 4, 8, 16 and 24hpa 367 
and neutrophils and macrophages were labeled and counted. To determine the number of cells 368 
that had migrated to the wounded area, cells posterior to the caudal vein were counted (area 369 
indicated by the red box in Fig.6A). 370 
In order to label the populations of neutrophils and macrophages in 3dpf larvae we 371 
employed Myeloperoxidase (Mpx) histochemistry, followed by immunofluorescent labeling of 372 
L-plastin. At this stage of development two populations of leukocytes are present: neutrophils, 373 
which are Mpx- and L-plastin-positive, and macrophages, which are Mpx-negative and L-374 
plastin-positive (31,33-35,58). Although neutrophils are stained by both methods, the L-plastin 375 
immunofluorescence is hard to detect in these cells due to the dark staining of the Mpx assay 376 
which hides the fluorescent signal. Using this approach, the number of macrophages and 377 
neutrophils were determined in the tail fins at different time points upon amputation. The results 378 
showed that macrophages migrated more to the posterior end of the tail where they appeared to 379 
line up at the actual wound site, whereas neutrophils were more randomly located in the vicinity 380 
of the wound (Fig.6B and 6C). 381 
 382 
The effect of GC treatment on amputation-induced leukocyte migration  383 
The results of the experiment described above revealed that both neutrophils and macrophages 384 
migrate towards the wounded area, but that their migratory behavior and response to 385 
beclomethasone are remarkably different. Analysis of our data revealed a migratory response of 386 
macrophages over time (as shown by a significant effect of time in an ANOVA (p<0.001)), but 387 
no effect of beclomethasone treatment was observed (Fig.7A). Macrophage migration increased 388 
rapidly after amputation, especially in the first 2 hours (9.7 ± 0.2 at 2hpa versus 4.0 ± 0.1 0hpa), 389 
and no decline was observed until 24hpa. For neutrophils, a migratory response was observed as 390 
well, which was inhibited by beclomethasone treatment (as shown by significant effects of time 391 
and beclomethasone treatment (both p<0.001)). Neutrophil migration reached a peak at 4hpa (7.4 392 
± 2.0 cells compared to 0.6 ± 0.1 at 0hpa) and rapidly decreased after this time point to 3.4 ± 0.6 393 
at 8hpa after which it remained stable at this level until 24hpa (Fig.7B). Beclomethasone 394 
treatment had a significant inhibitory effect on the neutrophil migration at 4hpa (4.3 ± 0.4 cells in 395 
the presence of beclomethasone). Based on these results, we concluded that both neutrophils and 396 
macrophages migrate towards wound sites, but that beclomethasone exhibits an inhibitory effect 397 
only on neutrophil migration. To establish whether beclomethasone specifically affects the 398 
migration of neutrophils rather than their total number, cells in the entire tail fin area (posterior 399 
to the yolk extension) were counted. The results of these countings did not show any significant 400 
difference in the number of neutrophils between vehicle- and beclomethasone-treated larvae 401 
upon amputation (Suppl.Fig.7), indicating a specific effect of beclomethasone on the neutrophil 402 
migration towards the wound site. 403 
In order to study whether the inhibition of neutrophil migration by beclomethasone was 404 
mediated by the GR, a mutant line grs357 was used which has a point mutation in the gene 405 
encoding the GR. This mutant receptor has been shown in in vitro studies to be unable to 406 
regulate gene transcription (54). Using this mutant line, neutrophil migration at 4hpa was 407 
determined in the absence and presence of beclomethasone. The results showed that 408 
beclomethasone had no effect on neutrophil migration in the mutant larvae (Fig.7C), indicating 409 
that the beclomethasone effect on the migration of neutrophils is mediated by the GR. 410 
Looking for differences between neutrophil and macrophage migration which may help 411 
to explain the difference in glucocorticoid responsiveness, we studied whether this migration was 412 
dependent on de novo protein synthesis. For this purpose, we administered the protein synthesis 413 
inhibitor cycloheximide and studied the effect of this treatment on macrophage and neutrophil 414 
migration at 4hpa (Fig.7D). Cycloheximide appeared to significantly inhibit both the 415 
macrophage and the neutrophil migration (as shown by a significant effect of treatment in an 416 
ANOVA (p=0.007 and p=0.013 respectively)). Apparently, the migration of both macrophages 417 
and neutrophils upon amputation depends on de novo protein synthesis.  418 
 In summary, macrophage migration appears to be dependent on de novo protein synthesis 419 
and is not inhibited by beclomethasone treatment. Therefore, macrophage migration must be 420 
dependent on the upregulation of genes of which this upregulation is not inhibited by 421 
beclomethasone. The most likely candidates are the four immune-related genes cd44, alox5ap, 422 
anxa1 and tlr4bb.  423 
Discussion 424 
 425 
In the present study, we have used zebrafish larvae in order to study the effects of GC signaling 426 
on the inflammatory response to tail fin amputation, both at the molecular and the cellular level. 427 
First, we looked for transcriptional changes at 4hpa and we identified 279 genes of which the 428 
expression was significantly altered upon amputation. The largest gene ontology group in this 429 
cluster of genes was formed by genes involved in the immune system, indicating that many of 430 
the observed changes are related to the induction of an inflammatory response. In a similar study 431 
by Yoshinari et al. (59), in which 2dpf embryos were tail fin amputated and samples were 432 
collected at a much later time point (16hpa), transcriptome analysis revealed that the largest 433 
fraction of regulated signaling routes were metabolic pathways (40%) and only a small fraction 434 
(2%) of signaling cascades regulated were immune-related. Thus, it appears that at 4 hours after 435 
injury, immune-related pathways are heavily activated at the transcriptional level, while 12 hours 436 
later amputation-induced changes in gene expression no longer reflect an inflammatory response. 437 
This is in line with the observed decline in neutrophil migration after 4hpa in our study. The 438 
second largest group was formed by genes encoding transcription factors, encompassing 439 
members of the AP-1 family and several other pro-inflammatory transcription factors.  440 
In contrast, in the presence of beclomethasone the transcriptional response to amputation 441 
is dramatically inhibited. From the 279 genes regulated by amputation, only 61 were still 442 
significantly regulated in the presence of beclomethasone, and for 86% of all amputation-443 
regulated probes an attenuated response to amputation was observed in the presence of 444 
beclomethasone. It must be noted that our data show that in general the transcriptional responses 445 
to tail fin injury are not completely blocked by beclomethasone, but that they are dampened. 446 
When we focused on the regulation of immune-related genes, it was found that the amputation-447 
induced regulation of only 4 genes was not attenuated by beclomethasone. Two of those genes, 448 
cd22 and anxa1a, are known to encode anti-inflammatory genes, but the other two, tlr4bb and 449 
alox5ap, encode proteins considered to be pro-inflammatory.  450 
In human cells, GCs have been shown to alter TLR signaling at different levels (60). The 451 
expression of the human tlr4 gene (like the trl2 gene) has been shown to be positively regulated 452 
by GCs in multiple human cell types in vitro (21,61). However, since GCs suppress the 453 
downstream signaling of these receptors, e.g. by inducing MKP-1 and GILZ/TCS22D1 or 454 
inhibiting transcription factors like AP-1, NF-κB and IRF (60), it has been argued that GCs 455 
ready the innate immune system by increasing the expression of TLRs, but repress inflammation 456 
by inhibiting the downstream signaling of these receptors (16). TLR ligands have been shown to 457 
stimulate cortisol secretion in mouse and human adrenal cells, which is abolished in TLR4-458 
deficient mice. It has therefore been suggested that the induction of tlr2 and tlr4 in the adrenal 459 
glands by GCs serves as a positive feedback loop, resulting in an increased cortisol release upon 460 
exposure to TLR ligands, which will eventually elicit mainly anti-inflammatory effects (60). 461 
Alox5ap is the activating protein for the enzyme alox5 which catalyzes the conversion of 462 
arachidonic acid (AA) into 5(S)-hydroperoxyeicosatetraenoic acid (5-HPETE) and LTA4 that 463 
can further be converted into LTB4, which plays an important role in the inflammatory response 464 
by acting as a chemoattractant for leukocytes. In several human and rat cell types, the expression 465 
of Alox5 and/or Alox5ap has been shown to be increased at the mRNA and protein level by 466 
dexamethasone treatment (62-65). However, the effect of GC treatment on the synthesis of pro-467 
inflammatory eicosanoids like LTB4 is less clear. In several in vivo and ex vivo studies on cells 468 
from human asthma patients, either no effect of GC treatment or a decrease in the concentration 469 
of eicosanoids like LTB4 was observed (66-68). In line with these data, we found that the 470 
amputation-induced increase in LTB4 concentration was inhibited by beclomethasone, although 471 
the steroid did not clearly affect the transcriptional regulation of proteins involved in LTB4 472 
biosynthesis. We also studied whether GCs stimulate conversion of LTA4 to lipoxinA4 (LXA4), 473 
an anti-inflammatory lipid which could contribute to the resolution of the inflammatory response 474 
(69,70). It was found that GCs did not affect LXA4levels, and did not have a clear effect on the 475 
mRNA levels of genes involved in LXA4 biosynthesis. Apparently, the LXA4 pathway is not a 476 
target for GCs, whereas LTB4 induction is inhibited by GCs. 477 
Finally, we examined the effect of GC treatment on the migration of leukocytes towards 478 
injured sites. Our analysis showed that beclomethasone treatment had a significant inhibitory 479 
effect only on the migration of neutrophils. Hence, the zebrafish model recapitulates the 480 
inhibitory effects of glucocorticoids on neutrophil migration towards inflamed tissues, that have 481 
been well established in mammalian models (71). However, macrophage migration was not 482 
inhibited by beclomethasone, in line with previously observed GC effects on leukocytes in 3dpf 483 
zebrafish larvae that were shown to be specifically suppressive regarding the recruitment of 484 
neutrophils but not of macrophages (51). It must be noted that macrophages are not a 485 
homogeneous cell population, but rather encompass distinct phenotypes. Macrophages with pro-486 
inflammatory activities are generally called M1 and those displaying anti-inflammatory action, 487 
thereby encouraging tissue repair, are called M2 (72). Interestingly, it has been shown that GC 488 
exposure induced a gene expression profile in human monocytes in which not only expression of 489 
pro-inflammatory genes was inhibited, but moreover expression of anti-inflammatory genes was 490 
induced (73). GC treatment has been shown to induce a highly phagocytic monocyte-derived 491 
macrophage phenotype, characterized by an increased expression of the scavenger receptor 492 
CD163 (73,74). We therefore suggest that the lack of effect of beclomethasone on macrophage 493 
migration should not be interpreted as a pro-inflammatory pathway that is resistant to GC 494 
treatment. However, GCs may induce differentiation of these macrophages towards an anti-495 
inflammatory phenotype, which may contribute to the resolution of the inflammation (75). 496 
Interestingly, in a recent study it has been shown that Anxa1 is able to recruit monocytes, by 497 
signaling through ALX/FPR2, which is the receptor for LXA4 (76). This suggests that the 498 
amputation-induced upregulation of anxa1 in our study which is not inhibited by beclomethasone 499 
may play an important role in the chemoattraction of macrophages. 500 
In summary, the zebrafish embryonic model of tail fin amputation and GC treatment 501 
constitutes a suitable system for studying GR signaling with respect to the innate immune 502 
response. In our model GCs appear to have a suppressive effect on the large majority of changes 503 
in gene transcription at 4hpa, which are mainly pro-inflammatory in nature, and this suppressive 504 
effect is reflected in a decreased neutrophil migration after 4hpa. Macrophage migration is not 505 
inhibited by GC treatment, and this migration may be a result of Anxa1 upregulation and 506 
increased production of anti-inflammatory eicosanoids. As a result, these macrophages may 507 
rather act anti-inflammatory, thereby resolving inflammation.  508 
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  704 
Figure legends 705 
Figure 1. A. The tail fin amputation assay. Schematic drawing of a zebrafish larvae at 3dpf, 706 
indicating the site of the tail fin amputation (red line).  B. Analysis of microarray experiment. 707 
Gene ontology groups represented in the clusters of genes regulated upon amputation. The 708 
results show that amputation mainly regulated genes involved in the immune system, genes 709 
encoding transcription factors, and genes involved in metabolism. Details on individual genes are 710 
presented in Suppl.Table2. C. Venn diagram showing overlaps between clusters of genes 711 
significantly regulated by amputation (amp), beclomethasone (beclo) and the combined 712 
amputation/beclomethasone treatment (amp+beclo). The diagram shows that there is a large 713 
overlap between the cluster of beclo-regulated genes and amp+beclo-regulated genes, but very 714 
little overlap between the amp-regulated cluster and the amp+beclo-regulated cluster. Data 715 
analysis was performed setting cutoffs for the p-value of <10-10 and for fold change of either >2 716 
or <-2 717 
 718 
Figure 2. Scatter plot showing the effect of beclomethasone treatment on amputation-induced 719 
alterations in gene expression. For all 2539 probes showing significant regulation upon 720 
amputation (comparison con/vehicle vs. 4hpa/vehicle, cutoff for the p-value of <10-10 and no 721 
cutoff for fold change), the fold change due to beclomethasone and amputation treatment 722 
(con/vehicle vs. 4hpa/beclo) was plotted as a function of the fold change due to amputation 723 
(con/veh vs. 4hpa/veh). The grey dashed line indicates the point at which beclomethasone 724 
treatment does not affect amputation-induced changes. Of the 2539 probes showing regulation 725 
by amputation (upregulation at right side of y-axis, downregulation at left side of y-axis), 86% 726 
shows an attenuation of this regulation in the presence of beclomethasone (indicated by red 727 
markers, probes of which the regulation is not attenuated by beclomethasone are indicated by 728 
green markers). These results show that in the vast majority of cases beclomethasone dampens 729 
the effects of amputation on gene expression. 730 
 731 
Figure 3. Regulation of genes involved in the immune system, determined using microarray 732 
analysis. For all 31 genes of which at least one probe was regulated significantly upon 733 
amputation, the average fold change due to amputation (amp, black bars), beclomethasone 734 
(beclo, black bars) and the combined amputation/beclomethasone treatment (amp+beclo, grey 735 
bars) was determined by averaging the fold change for all probes representing this gene present 736 
on the microarray. The results show that beclomethasone dampens the amputation-induced 737 
expression of 27 genes, but for 4 genes (indicated by grey boxes) amp+beclo treatment results in 738 
higher fold change compared to amp treatment.  739 
 740 
Figure 4. A. Leukotriene B4 (LTB4) biosynthesis pathway. Arachidonic acid (AA) is converted 741 
into 5(S)-hydroperoxyeicosatetraenoic acid (5-HPETE) by Arachidonate 5-lipoxygenase 742 
(Alox5). In zebrafish, four genes (alox5a, alox5b.1-3) encode four different Alox5 isoforms.  5-743 
HPETE is converted into LTA4, which can be converted into LTB4 by Leukotriene A4 744 
hydrolase (LTA4H). B. Whole body LTB4 concentrations measured in 3dpf larvae by ELISA. 745 
Statistical analysis (ANOVA) showed a significant increase upon amputation only in the vehicle-746 
treated groups. An interaction between amputation and beclomethasone treatment was observed 747 
(p=0.01). C. Validation of alox5ap gene regulation by qPCR. Statistical analysis showed that 748 
alox5ap mRNA expression was significantly altered by amputation (p=0.04), and that there was 749 
no effect of beclomethasone treatment (and no interaction between amputation and 750 
beclomethasone treatment). D. Expression levels of alox5a determined by qPCR. A significant 751 
effect of amputation was observed. E. Expression levels of lta4h determined by qPCR. A 752 
significant effect of both amputation and beclomethasone treatment was observed. * Statistically 753 
significant difference compared to control treatment (Bonferroni post hoc comparison, p<0.01). 754 
 755 
Figure 5. A. Lipoxin A4 (LXA4) biosynthesis pathway. LXA4 can be synthesized from LTA4. 756 
In zebrafish, three genes encode enzymes that may be involved in this conversion:  arachidonate 757 
12-lipoxygenase (alox12), alox12b, and arachidonate 15-lipoxygenase b (alox15b). These 758 
enzymes may also convert AA to 15-Hydroxyicosatetraenoic acid (15S-HETE), which can 759 
subsequently be converted into LXA4 by Alox5 (70). B. Whole body LXA4 concentrations 760 
measured in 3dpf larvae by ELISA. Statistical analysis (ANOVA) showed an effect of 761 
amputation (p=0.01). C. Expression levels of alox12 determined by qPCR. A significant 762 
interaction between amputation and beclomethasone treatment was observed. D. Expression 763 
levels of alox12b determined by qPCR. A significant effect of amputation was observed. D. 764 
Expression levels of alox15b determined by qPCR. A significant effect of amputation was 765 
observed. * Statistically significant difference compared to control treatment (Bonferroni post 766 
hoc comparison, p<0.05).  767 
 768 
Figure 6. A. Schematic drawing of a zebrafish larvae at 3dpf, indicating the area selected for 769 
counting the number of neutrophils and macrophages that had migrated to the wounded area (red 770 
box, CV=caudal vein). B. Leukocyte staining upon tail fin amputation in a 3dpf embryo by 771 
immunohistochemistry against the pan-leukocyte marker L-plastin (shown in red). C. Staining of 772 
neutrophils specifically by Mpx staining (shown in black). Neutrophils are stained by both 773 
methods, but the L-plastin immunolabeling is hard to detect in these cells due to the dark staining 774 
of the Mpx assay. Therefore, the number of neutrophils was determined by counting in the cells 775 
stained by the Mpx assay (shown black in B and C) and the number of macrophages was 776 
determined by counting the number of cells stained by the L-plastin immunohistochemistry 777 
(shown red in B). Further details on the analysis of this labeling can be found in Suppl.Fig.6. 778 
 779 
Figure 7. Leukocyte migration upon tail fin amputation in 3dpf zebrafish larvae, and the effect 780 
of beclomethasone treatment on this migration. A. The number of macrophages in the wounded 781 
area as a function of time after amputation. Statistical analysis by two-way ANOVA revealed a 782 
migratory response of macrophages over time (p<0.001), but no effect of beclomethasone on this 783 
response. B. The number of neutrophils in the wounded area as a function of time after 784 
amputation. Statistical analysis by two-way ANOVA revealed that both beclomethasone 785 
treatment and time had a significant effect on the number of neutrophils (both p<0.001), and that 786 
the neutrophil number was significantly increased at 4hpa compared to the 0hpa time point 787 
(p<0.001). C. Neutrophil migration in GR mutant (grs357) larvae. The number of neutrophils in 788 
the wounded area is shown at 4 hours post amputation in wild type and grs357 larvae. No effect of 789 
beclomethasone was observed in the mutant larvae, whereas beclomethasone significantly 790 
decreased the number of neutrophils in the wild types. D. The effect of cycloheximide treatment 791 
on macrophage and neutrophil migration. Macrophage and neutrophil numbers in the wounded 792 
area are shown at 4hpa, after vehicle (black bars) or cycloheximide (grey bars) treatment. 793 
Statistical analysis by ANOVA revealed a significant effect of cycloheximide treatment on both 794 
the macrophage and the neutrophil migration (p<0.05). * Statistically significant difference 795 
compared to vehicle treatment (p<0.05). 796 
